Author

S. Baisiwala

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 5

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 4 Organism:human· 4 Assay:bulk RNA-seq· 2 Approach:experimental assay· 2 Approach:genetic perturbation / CRISPR· 2 Organism:mouse· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1

Frequent Co-Authors

A. U. Ahmed· 4 shared C. Park· 4 shared C. D. James· 3 shared J. M. Shireman· 3 shared S. Budhiraja· 3 shared A. Sonabend· 2 shared A. Zolp· 2 shared C. Dmello· 2 shared

Activity by Year

2018-2021 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 35 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

A. U. Ahmed

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Ribonucleotide Reductase Regulatory Subunit M2 as a Driver of Glioblastoma TMZ-Resistance through Modulation of dNTP Production

E. N. Perrault, J. M. Shireman, E. S. Ali, I. Preddy, P. Lin, C. Park, L. Tomes, A. J. Zolp, S. Budhiraja, S. Baisiwala, C. D. James, I. Ben-Sahra, S. Pott, A. Basu, A. U. Ahmed

This study identifies RRM2 as a driver of TMZ resistance in GBM by modulating dNTP production, showing RRM2 inhibition enhances TMZ efficacy in vivo.

bioRxiv · Nov 23, 2021 · PreprintCancer Biology

CRISPR-Cas9 Screen Reveals PSMB3 Contributes to Gliomagenesis Through Proteasome-Dependent and Independent Mechanisms

S. Baisiwala, S. Budhiraja, A. Zolp, K. Nandoliya, L. Chen, C. Park, E. Perrault, M. Saathoff, C. Dmello, J. Shireman, P. Lin, G. Dara, K. McCortney, C. Horbinski, A. Sonabend, A. U. Ahmed

The paper identifies PSMB3 as a contributor to gliomagenesis through proteasome-dependent and independent mechanisms using a CRISPR-Cas9 screen in GBM.

bioRxiv · Jul 28, 2021 · PreprintCancer Biology

ARF4-mediated Retrograde Trafficking Drives Chemoresistance in Glioblastoma

S. Budhiraja, S. Baisiwala, E. Perrault, S. Cho, K. Nandoliya, G. Dara, A. Zolp, L. Chen, C. Dmello, C. Park, A. Sonabend, A. Ahmed

This study identifies ARF4 as a driver of chemoresistance in glioblastoma through a CRISPR screen and shows it mediates retrograde trafficking of EGFR into the nucleus.

bioRxiv · Jul 18, 2021 · PreprintCancer Biology

Interleukin-8/CXCR2 signaling regulates therapy-induced plasticity and enhances tumorigenicity in glioblastoma

T. Hasan, S. P. Caragher, J. M. Shireman, C. H. Park, F. Atashi, S. Baisiwala, G. Lee, D. Guo, M. Wu, J. Y. Wang, M. Dey, M. S. Lesniak, C. M. Horbinski, C. D. James, A. U. Ahmed

This study shows IL-8 promotes cellular plasticity and therapeutic resistance in glioblastoma by altering epigenetic marks and enhancing cancer initiating cell properties.

bioRxiv · Nov 16, 2018Cancer Biology

Activation of dopamine receptor 2 (DRD2) prompts transcriptomic and metabolic plasticity in glioblastoma

S. P. Caragher, J. M. Shireman, M. Huang, J. Miska, S. Baisiwala, C. Park, M. Saathoff, L. Warnke, T. Xiao, M. S. Lesniak, C. D. James, H. Meltzer, A. K. Tryba, A. U. Ahmed

This paper shows that dopamine receptor 2 activation in glioblastoma cells increases their growth, stemness, and metabolic activity, suggesting dopamine signaling as a therapeutic target.

bioRxiv · Nov 16, 2018Cancer Biology